Brookline Capital Markets has expanded its healthcare investment banking services team with five new hires. Joining the company are Dr. Kumar Raja as senior biotechnology analyst; Graham A. Powis as senior capital markets adviser; Dr. Samuel P. Wertheimer as senior scientific adviser; Michael D. Rhea as managing director of institutional sales; and Joseph A. LaSala as senior associate of investment banking.
NEW YORK–(BUSINESS WIRE)–Brookline Capital Markets (“Brookline”) is pleased to announce the recent expansion of its healthcare investment banking services and team. Brookline has a strong established business of raising private equity for both private and public life sciences, medical technology and diagnostics companies, advising on mergers and acquisitions, and participating in public offerings. Building on its success, Brookline has recently increased its services to include publishing equity research and underwriting public securities offerings, including IPOs and secondary offerings. In order to support this continued growth. Brookline has made five key appointments: Kumar Raja, Ph.D. has joined as Senior Biotechnology Analyst; Graham A. Powis has joined as Senior Capital Markets Advisor; Samuel P. Wertheimer, Ph.D. has joined as Senior Scientific Advisor; Michael D. Rhea has joined as Managing Director, Institutional Sales; and Joseph A. LaSala has joined as Senior Associate, Investment Banking.
“We are thrilled to welcome these experienced veterans and talented professionals to our growing healthcare team,” said William Buchanan, Jr., Managing Partner of Brookline Capital Markets. “The addition of these professionals underscores our commitment to providing our clients the best possible financial solutions, as well as thoughtful analysis and research. These are exciting times in health care, and we see enormous untapped opportunity in the markets.”
“The addition of these professionals underscores our commitment to providing our clients the best possible financial solutions, as well as thoughtful analysis and research. These are exciting times in health care, and we see enormous untapped opportunity in the markets.”
Kumar Raja, Ph.D. joins Brookline from Noble Life Science Partners and prior to that, Citigroup. He is an experienced research professional with a focus on fundamental equity analysis of biotechnology and pharmaceutical companies. His research leverages a unique combination of expertise in deep scientific analysis, medical markets, and competitive analysis. Graham Powis was most recently Head of Investment Banking at BTIG. Previously, he spent seven years at Lazard as Head of U.S. Equity Capital Markets and, prior to that, nine years at Cowen & Co. where he ultimately ran the Equity Capital Markets division as a market leader in health care underwriting. Samuel Wertheimer, Ph.D. is a 25-year veteran of life sciences investing, including 12 years as a Venture Partner with Orbimed Advisors in New York where he vetted investment opportunities for Orbimed’s flagship private equity fund and private placements for their public funds. Michael Rhea is a 30-year veteran of Wall Street and has enjoyed a successful career in institutional sales and capital markets activities, having served in a variety of roles at Lehman Brothers, Soleil Securities and Oppenheimer & Co. Joseph LaSala was most recently Global Equity Capital Markets Analyst at Monashee Investment Management in Boston, MA. where he spent the last five years analyzing investments and expanding the firm’s global footprint.
About Brookline Capital Markets
Brookline Capital Markets, a division of CIM Securities, provides a comprehensive suite of capital markets and advisory services to transformative emerging growth companies, with an emphasis on the life sciences, medical technology and diagnostics sectors. Headquartered in New York City, the firm seeks opportunities to accelerate growth for its client companies while delivering results to its sophisticated investor base. Brookline differentiates itself by its ability to source capital from traditional institutional investors, as well as from its proprietary global network of family office and high net worth investors.